References
- Bagdy, G. 1995. Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behavioural Brain Research 73 (1–2):277–80.
- Cameron, L. P., A. Nazarian, and D. E. Olson. 2020. Psychedelic microdosing: Prevalence and subjective effects. Journal of Psychoactive Drugs 52 (2):113–22.
- Delcour, C., G. Robin, J. Young, and D. Dewailly. 2019. PCOS and hyperprolactinemia: What do we know in 2019? Clinical Medicine Insights: Reproductive Health 13:1179558119871921.
- de Menezes, G., A. Cecília, R. N. de Almeida, D. S. Silva, E. Allan, D. M. Freire, F. Aurélio, F. Palhano-Fontes, H. Onias, E. Arcoverdee, et al. 2018. A single dose of ayahuasca modulates salivary cortisol in treatment-resistant depression. bioRxiv 257238 doi:10.3389/fpsyt.2018.00185.
- Fadiman, J., and S. Korb. 2019. Microdosing psychedelics. Advances in Psychedelic Medicine: State-Of-The-Art Therapeutic Applications 318.
- Fanchamps, A. 1976. Mechanism of action of drugs currently used in the prevention of migraine. Minerva medica 67 (28):1858–60.
- Gaddum, J. H., and K. A. Hameed. 1954. Drugs which antagonize 5-hydroxytryptamine. British Journal of Pharmacology and Chemotherapy 9 (2):240.
- Gouzoulis-Mayfrank, E., M. Schreckenberger, O. Sabri, C. Arning, B. Thelen, M. Spitzer, K. A. Kovar, L. Hermle, U. Bll, and H. Sass. 1999. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and D-methamphetamine in healthy volunteers. a double-blind, placebo-controlled PET study with 18F]FDG. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 20 (6):565. http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=10327426&site=ehost-live&scope=site
- Hasin, D. S., A. L. Sarvet, J. L. Meyers, T. D. Saha, W. June Ruan, M. Stohl, and B. F. Grant. 2018. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 75 (4):336–46.
- Homburg, R., and V. Insler. 2002. Ovulation induction in perspective. Human Reproduction Update 8 (5):449–62.
- Hull, M. G., P. E. Savage, and H. S. Jacobs. 1979. Investigation and treatment of amenorrhoea resulting in normal fertility. British Medical Journal 1 (6173):1257–61.
- Johnson, M. W., P. S. Hendricks, F. S. Barrett, and R. R. Griffiths. 2019. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics 197:83–102.
- Kamberi, I. A., R. S. Mical, and J. C. Porter. 1971. Effects of melatonin and serotonin on the release of FSH and prolactin. Endocrinology 88 (6):1288–93.
- Levine, S., and O. Muneyyirci-Delale. 2018. Stress-induced hyperprolactinemia: Pathophysiology and clinical approach. Obstetrics and Gynecology International 2018:1–6.
- McNeilly, A. S. 1980. Prolactin and the control of gonadotrophin secretion in the female. Reproduction 58 (2):537–49.
- Müller-Schweinitzer, E., and C. Tapparelli. 1986. Methylergometrine, an active metabolite of methysergide. Cephalalgia 6 (1):35–41. doi:10.1046/j.1468-2982.1986.0601035.x.
- Quadri, S. K., and J. Meites. 1971. LSD-induced decrease in serum prolactin in rats. Proceedings of the Society for Experimental Biology and Medicine 137 (4):1242–43. doi:10.3181/00379727-137-35764.
- Salerno, E. V., and A. Tallaferro. 1957. Mescalina, dietilamida del acido D-Lisergico (LSD 25) Y funcion menstrual. La Semana medica 110 (2):47–52.
- Sandison, R. A., A. M. Spencer, and J. D. A. Whitelaw. 1954. The therapeutic value of lysergic acid diethylamide in mental illness. The Journal of Mental Science 100 (419):491–507.
- Strassman, R. J., C. R. Qualls, and L. M. Berg. 1996. Differential tolerance to biological and subjective effects of four closely spaced doses of N, N-Dimethyltryptamine in humans. Biological Psychiatry 39 (9):784–95.
- Webster, J., G. Piscitelli, A. Polli, C. I. Ferrari, I. Ismail, and M. F. Scanlon. 1994. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. The New England Journal of Medicine 331 (14):904–09.
- Xiao, B., H. von Hertzen, H. Zhao, and G. Piaggio. 2003. Menstrual induction with mifepristone and misoprostol. Contraception 68 (6):489–94.
- Zawilska, J. B., M. Kacela, and P. Adamowicz. 2020. Nbomes–highly potent and toxic alternatives of LSD. Frontiers in neuroscience 14 78 doi:10.3389/fnins.2020.00078.